<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00041249</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-62011</org_study_id>
    <secondary_id>EORTC-62011</secondary_id>
    <nct_id>NCT00041249</nct_id>
  </id_info>
  <brief_title>Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma</brief_title>
  <official_title>Efficacy And Safety Study Of Brostallicin In Patients With Locally Advanced Or Metastatic Soft Tissue Sarcoma Failing One Prior Chemotherapy Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of brostallicin in treating patients who&#xD;
      have locally advanced or metastatic soft tissue sarcoma that has not responded to one&#xD;
      previous chemotherapy regimen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the antitumor activity of brostallicin, in terms of objective response, in&#xD;
           patients with locally advanced or metastatic soft tissue sarcoma who have failed one&#xD;
           prior chemotherapy treatment.&#xD;
&#xD;
        -  Determine the time to progression and duration of response in patients treated with this&#xD;
           drug.&#xD;
&#xD;
        -  Determine the safety and toxic effects of this drug in these patients.&#xD;
&#xD;
        -  Correlate clinical outcome with whole blood glutathione level in patients treated with&#xD;
           this drug.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to tumor (tumors&#xD;
      other than gastrointestinal stromal tumor (GIST) vs GIST).&#xD;
&#xD;
      Patients receive brostallicin IV over 10 minutes on day 1. Treatment repeats every 21 days&#xD;
      for at least 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 2 months for 1 year and then every 4 months for 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 58-72 patients (40 for stratum I and 18-32 for stratum II) will&#xD;
      be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <primary_completion_date type="Actual">January 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">64</enrollment>
  <condition>Gastrointestinal Stromal Tumor</condition>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>brostallicin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed soft tissue sarcoma that is not amenable to surgery,&#xD;
             radiotherapy, or combined modality therapy with curative intent&#xD;
&#xD;
          -  Stratum I&#xD;
&#xD;
               -  Malignant fibrous histiocytoma&#xD;
&#xD;
               -  Liposarcoma&#xD;
&#xD;
               -  Rhabdomyosarcoma&#xD;
&#xD;
               -  Synovial sarcoma&#xD;
&#xD;
               -  Malignant paraganglioma&#xD;
&#xD;
               -  Fibrosarcoma&#xD;
&#xD;
               -  Leiomyosarcoma&#xD;
&#xD;
               -  Angiosarcoma including hemangiopericytoma&#xD;
&#xD;
               -  Malignant peripheral nerve sheath tumor&#xD;
&#xD;
               -  Unclassified sarcoma&#xD;
&#xD;
               -  Miscellaneous sarcoma&#xD;
&#xD;
          -  Stratum II&#xD;
&#xD;
               -  Gastrointestinal stromal tumor&#xD;
&#xD;
               -  Previously treated with imatinib mesylate for locally advanced or metastatic&#xD;
                  disease and demonstrated disease progression&#xD;
&#xD;
          -  The following sarcoma types are excluded:&#xD;
&#xD;
               -  Mixed mesodermal tumors of the uterus (and carcinosarcoma)&#xD;
&#xD;
               -  Chondrosarcoma&#xD;
&#xD;
               -  Malignant mesothelioma&#xD;
&#xD;
               -  Neuroblastoma&#xD;
&#xD;
               -  Osteosarcoma&#xD;
&#xD;
               -  Ewing's sarcoma&#xD;
&#xD;
               -  Embryonal rhabdomyosarcoma&#xD;
&#xD;
          -  At least one measurable lesion&#xD;
&#xD;
          -  Progressive disease after 1 prior anthracycline- and/or alkylating-containing&#xD;
             chemotherapy regimen for locally advanced or metastatic disease&#xD;
&#xD;
          -  Clinical evidence of progression within 6 weeks prior to study treatment&#xD;
&#xD;
          -  No known or symptomatic CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Over 15&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  WHO 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 4,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.25 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGPT and SGOT no greater than 3 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.4 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance greater than 65 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No prior severe cardiovascular disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for up to 6 months after&#xD;
             study&#xD;
&#xD;
          -  No other prior or concurrent malignancy except adequately treated basal cell skin&#xD;
             cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No other severe medical illness&#xD;
&#xD;
          -  No psychosis&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent biologic response modifiers or immunotherapy&#xD;
&#xD;
          -  No concurrent prophylactic hematopoietic growth factors (e.g., filgrastim (G- CSF) or&#xD;
             sargramostim (GM-CSF)&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy and recovered&#xD;
&#xD;
          -  Prior adjuvant chemotherapy as first-line treatment allowed provided disease&#xD;
             progressed within 6 months after the completion of chemotherapy&#xD;
&#xD;
          -  No prior ecteinascidin 743 (stratum I)&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to sole measurable lesion&#xD;
&#xD;
          -  Concurrent palliative radiotherapy to nontarget lesions allowed at investigator's&#xD;
             discretion&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent anticancer therapy (approved or investigational)&#xD;
&#xD;
          -  No concurrent participation in any other clinical treatment study&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Leahy, MBChB, FRACP, FRCP, FRC Path</last_name>
    <role>Study Chair</role>
    <affiliation>Fremantle Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Roessle Klinik</name>
      <address>
        <city>Berlin</city>
        <zip>D-13122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaets-Krankenhaus Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>D-30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Grosshadern der Ludwig-Maximilians Universitaet Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daniel Den Hoed Cancer Center at Erasmus University Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3008 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Trust - London</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Centre for Cancer Treatment at Newcastle General Hospital</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <state>England</state>
        <zip>NE4 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Leahy M, Ray-Coquard I, Verweij J, Le Cesne A, Duffaud F, Hogendoorn PC, Fowst C, de Balincourt C, di Paola ED, van Glabbeke M, Judson I, Blay JY; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2007 Jan;43(2):308-15. Epub 2006 Nov 13.</citation>
    <PMID>17095209</PMID>
  </results_reference>
  <results_reference>
    <citation>Leahy MG, Blay JY, Verweij J, et al.: EORTC 62011: phase II trial of brostallicin for soft tissue sarcoma. [Abstract] Eur J Cancer Suppl 1 (5): S209, A-694, 2003.</citation>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>July 8, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 17, 2012</last_update_submitted>
  <last_update_submitted_qc>July 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult angiosarcoma</keyword>
  <keyword>adult fibrosarcoma</keyword>
  <keyword>adult leiomyosarcoma</keyword>
  <keyword>adult liposarcoma</keyword>
  <keyword>adult neurofibrosarcoma</keyword>
  <keyword>adult synovial sarcoma</keyword>
  <keyword>stage III adult soft tissue sarcoma</keyword>
  <keyword>recurrent adult soft tissue sarcoma</keyword>
  <keyword>adult malignant fibrous histiocytoma</keyword>
  <keyword>adult malignant hemangiopericytoma</keyword>
  <keyword>adult rhabdomyosarcoma</keyword>
  <keyword>gastrointestinal stromal tumor</keyword>
  <keyword>stage IV adult soft tissue sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

